Aerie Pharmaceuticals to Present at 31st Annual J.P. Morgan Healthcare Conference

JPMorgan Healthcare Conference 2013

BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.--()--Aerie Pharmaceuticals, Inc. announced today that Thomas van Haarlem, M.D., Aerie’s President and Chief Executive Officer, will present an overview and update of the Company’s novel glaucoma therapies at the 31st Annual J.P. Morgan Healthcare Conference on Thursday, January 10 at 1:00 pm PT at the Westin St. Francis Hotel in San Francisco.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals is a privately held pharmaceutical company in late Phase 2 dedicated to the discovery and development of novel small-molecule treatments for glaucoma. Aerie’s internal research and development engine has generated an innovative glaucoma pipeline of three proprietary products, all of which are well tolerated, high efficacy, once-daily eye drop therapies that include the first new mechanisms of action for glaucoma treatment in nearly 20 years. Aerie’s products have blockbuster potential within the $4 billion U.S. / E.U. market and are expected to commence commercialization by 2016.

The Company’s lead product candidate, AR-12286, is a highly selective Rho Kinase inhibitor that is the first glaucoma therapy to reduce intraocular pressure by relaxing and clearing the trabecular meshwork, which is the eye’s main fluid drain. AR-12286 is expected to be the new, convenient second-line glaucoma drug of choice, in a market where nearly half of patients require second-line or add-on therapy. Aerie’s PG286 fixed combination with travoprost is the first glaucoma therapy to lower intraocular pressure by opening both of the eye’s fluid drains. This new second-line therapy offers the convenience of two drugs in one eye drop and the highest efficacy of any single drop glaucoma medication. The Company’s third product, AR-13324, is a potential first line therapy and the first of a new dual action drug class that reduces the eye’s fluid inflow while also increasing fluid outflow through the trabecular meshwork drain, all in a highly effective single drop per day.

Aerie is located in Bedminster, New Jersey and Research Triangle Park, North Carolina. Further information on the Company is available at www.aeriepharma.com.

Contacts

Aerie Pharmaceuticals
Thomas van Haarlem, 908-470-4320
President and Chief Executive Officer
or
Burns McClellan, Inc.
Justin Jackson, 212-213-0006
jjackson@burnsmc.com

Release Summary

Aerie Pharmaceuticals will present an overview and update of the Company’s novel glaucoma therapies at the 31st Annual J.P. Morgan Healthcare Conference.

Sharing

Contacts

Aerie Pharmaceuticals
Thomas van Haarlem, 908-470-4320
President and Chief Executive Officer
or
Burns McClellan, Inc.
Justin Jackson, 212-213-0006
jjackson@burnsmc.com